CORD-19:35349bb1fc9290338907b7d7f104c9db3951163b / 1056-1339 JSONTXT

{"project":"CORD-PICO","denotations":[{"id":"p1_all10","span":{"begin":50,"end":68},"obj":"Intervention"},{"id":"p1_all11","span":{"begin":94,"end":117},"obj":"Outcome"},{"id":"p1_all12","span":{"begin":121,"end":141},"obj":"Intervention"},{"id":"p1_all13","span":{"begin":145,"end":205},"obj":"Population"},{"id":"p1_all14","span":{"begin":244,"end":253},"obj":"Intervention"},{"id":"p2_p0","span":{"begin":155,"end":198},"obj":"Condition"},{"id":"p2_i7","span":{"begin":50,"end":68},"obj":"Control"},{"id":"p2_i8","span":{"begin":134,"end":141},"obj":"Control"}],"text":"The aim of this prospective, blinded, randomized, placebo-controlled study was to compare the pharmacodynamic effects of Entresto® to placebo in dogs with preclinical myxomatous mitral valve disease (MMVD) and to evaluate the safety profile of Entresto® in dogs with cardiac disease."}

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T6","span":{"begin":0,"end":283},"obj":"Sentence"},{"id":"T97188","span":{"begin":0,"end":283},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The aim of this prospective, blinded, randomized, placebo-controlled study was to compare the pharmacodynamic effects of Entresto® to placebo in dogs with preclinical myxomatous mitral valve disease (MMVD) and to evaluate the safety profile of Entresto® in dogs with cardiac disease."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T5","span":{"begin":178,"end":190},"obj":"Body_part"},{"id":"T6","span":{"begin":185,"end":190},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0002135"},{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0003978"}],"text":"The aim of this prospective, blinded, randomized, placebo-controlled study was to compare the pharmacodynamic effects of Entresto® to placebo in dogs with preclinical myxomatous mitral valve disease (MMVD) and to evaluate the safety profile of Entresto® in dogs with cardiac disease."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T6","span":{"begin":178,"end":198},"obj":"Disease"},{"id":"T7","span":{"begin":200,"end":204},"obj":"Disease"},{"id":"T8","span":{"begin":267,"end":282},"obj":"Disease"},{"id":"T82938","span":{"begin":178,"end":198},"obj":"Disease"},{"id":"T80976","span":{"begin":200,"end":204},"obj":"Disease"},{"id":"T49525","span":{"begin":267,"end":282},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0003767"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0003767"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005267"},{"id":"A72013","pred":"mondo_id","subj":"T82938","obj":"http://purl.obolibrary.org/obo/MONDO_0003767"},{"id":"A98976","pred":"mondo_id","subj":"T80976","obj":"http://purl.obolibrary.org/obo/MONDO_0003767"},{"id":"A94695","pred":"mondo_id","subj":"T49525","obj":"http://purl.obolibrary.org/obo/MONDO_0005267"}],"text":"The aim of this prospective, blinded, randomized, placebo-controlled study was to compare the pharmacodynamic effects of Entresto® to placebo in dogs with preclinical myxomatous mitral valve disease (MMVD) and to evaluate the safety profile of Entresto® in dogs with cardiac disease."}